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Abstract. The Schistosomiasis Consortium for Operational Research (SCORE) was funded in 2008 to improve the
evidence base for control and elimination of schistosomiasis—better understanding of the systemic morbidities expe-
rienced by children in schistosomiasis-endemic areas and the response of thesemorbidities to treatment, being essential
for updating WHO guidelines for mass drug administration (MDA) in endemic areas. This article summarizes the SCORE
studies that aimed to gauge the impact of MDA-based treatment on schistosomiasis-related morbidities. Morbidity
cohort studies were embedded in the SCORE’s larger field studies of gaining control of schistosomiasis in Kenya and
Tanzania. FollowingMDA, cohort children had less undernutrition, less portal vein dilation, and increased quality of life in
Year 5 compared with baseline. We also conducted a pilot study of the Behavioral Assessment System for Children
(BASC-2) in conjunction with the Kenya gaining control study, which demonstrated beneficial effects of treatment on
classroom behavior. In addition, the SCORE’s Rapid Answers Project performed systematic reviews of previously
available data, providing two meta-analyses related to morbidity. The first documented children’s infection-related
deficits in school attendance and achievement and in formal tests of learning and memory. The second showed that
greater reductions in egg output following drug treatment correlates significantly with reduced odds of most morbidities.
Overall, theseSCOREmorbidity studies provided convincing evidence to support the use ofMDA to improve the health of
school-aged children in endemic areas. However, study findings also support the need to use enhanced metrics to fully
assess and better control schistosomiasis-associated morbidity.
OVERVIEW
The Schistosomiasis Consortium for Operational Research
(SCORE) was funded in 2008 to improve the evidence base for
control and elimination of schistosomiasis.1 As part of its mis-
sion, the SCORE sought to develop a better understanding
of theanatomicandsystemic functionalmorbiditiesexperienced
by people at risk in schistosomiasis-endemic areas and their
response to antischistosomal praziquantel treatment. Such data
are essential for updating WHO guidelines for schistosomiasis
control andmaking the case formassdrug administration (MDA)
in endemic areas. This article reviews and summarizes the re-
sults of the SCORE-supported projects that detailed specific
human health impacts of Schistosoma infection and their re-
sponse to treatment.
People living in schistosomiasis-endemicareasmayspendone-
third to a half of their lives carrying Schistosoma parasitic worms
because their continuing environmental exposure leads to over-
lapping schistosome infections.2 Morbidity associated with schis-
tosomiasis is causedby parasite eggs that are deposited daily into
the human host’s organs, creating thousands of foci of granu-
lomatous inflammation, particularly in the bowel and liver
(Schistosoma mansoni, Schistosoma mekongi, and Schistosoma
japonicum) or urogenital organs (Schistosoma haematobium).
Although these granulomas can cause critical dysfunction of the
affected organs, more frequently, the granuloma’s chronic in-
flammation contributes to multiple systemic deficits, including
chronic pain,3,4 diarrhea,3 fatigue,5,6 reduced quality of life,7,8
anemiaof chronic inflammation,9 impairedchildhoodgrowthand
development,10,11 blunted response to childhood vaccines,12,13
and impaired school performance.14,15 The disease impact can
becomepermanent, persisting even after the active infection has
resolved.16 Often overlooked as part of S. haematobium–
associated morbidity, genital schistosomiasis with pain, bleed-
ing,17 and subfertility18 can result in increased rates of HIV
transmission.19
Current WHO strategies for schistosomiasis morbidity control
focus on regular delivery of antischistosomal drugs to at-risk
populations as a form of “preventive chemotherapy” to limit (or
even reverse) the impact of active infection and to prevent new
disease sequelae from developing.20,21 Prioritization for control
of neglected tropical diseases such as schistosomiasis is often
carried out using disability-adjusted life years (DALYs) within in-
ternational governmental and nongovernmental programs.22,23
The DALY construct is based on the perceived disability and
persistence of a condition and is used to rank the relative con-
tribution of different disabling conditions to the overall global
burden of disease.21,24 The DALY rankings are sometimes as-
sumed to reflect the importance of a given disease to world
health.25 The DALYs attributed to schistosomiasis are derived
primarily on the prevalence of classic organ-specific chronic
anatomicpathologiesof schistosomiasis (hepatosplenicdisease
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and bladder fibrosis) observed in the most severe chronic in-
fections, and not on the systemic functional conditions that are
also related to Schistosoma infection. In response, SCORE re-
searchers decided to use an expanded set of metrics for mor-
bidity appraisals during the course of their MDA trials. These
included nutrition and growth assessments, anemia testing, ex-
ercise capacity, and formalmeasurementof school behavior and
of health-related quality of life before and after treatment.26 The
impact of disease-associated stigma and depression,27 espe-
cially related to female and male genital schistosomiasis, is un-
doubtedly part of the disabling impact of schistosomiasis.
Unfortunately, SCORE resources did not allow for study of these
latter effectsnorwas thereasufficient timeline toevaluate the link
between Schistosoma infection and long-term focal and sys-
temic pathologies that persist beyond the period of active
infection.28
Underlying all SCORE projects was the goal of providing data
that would provide evidence to help program managers make
decisions related to controlling and eliminating schistosomiasis.
A related issue was providing evidence that would convince
ministers in endemic countries to prioritize schistosomiasis
treatment and prevention. Given the underestimation of DALYs
related to schistosomiasis, in part related to the lack of high-
quality data on the impact of lower intensity infections and the
lifetime consequences, the SCORE saw the need to revisit and
contribute data to help redefine schistosomiasis “morbidity”
based on newer developments in the field. Its specific aimwas to
reevaluate how regular MDA could improve the health of school-
agedchildren inschistosomiasis-endemicareas.26Asa result, the
SCORE portfolio related to morbidity and its control included
separate longitudinal cohort studies, a school behavioral assess-
ment study, and two systematic reviews and meta-analyses of
previouslypublisheddataon infection-relatedmorbidityoutcomes.
SCHISTOSOMIASIS CONSORTIUM FOR OPERATIONAL
RESEARCH LONGITUDINAL COHORT STUDIES
Because there were few clinical research studies evaluating
the long-termbenefits of praziquantel in termsof prevention of
new disease or amelioration of existing disease, SCORE
partners incorporated nested comparison studies of the im-
pact of MDA on Schistosoma infection–associated morbidity
in school-aged children in each of the SCORE prospective
randomized gaining control studies.26
The gaining control studies were large, cluster-randomized
studies, with communities randomized to receive either two
or four MDAs during a 4-year intervention period, with a
follow-up assessment in Year 5.29 The morbidity cohort
studies discussed here were conducted in the gaining con-
trol studies in Kenya and Tanzania and included four to six
communities from the study arm receiving themost intensive
treatment (4 years of MDA through community-wide treat-
ment [CWT]) compared with four communities from an arm
receiving standard every-other-year MDA through school-
based treatment (SBT).26 Morbidity studies were also initi-
ated in the gaining control studies in Niger andMozambique,
but these were discontinued after baseline data were col-
lected because of a failure to appropriately randomize
communities in Niger (resulting in dramatically different
starting prevalences among study arms) and to extremely
high loss to follow-up rates in Mozambique related to very
low school attendance there.
One hundred 7- to 8-year-old children per community were
targeted for enrollment at baseline (Year 1) for the cohort
studies, with a goal of having 800 children prospectively
monitored in each country.26 The decision to focus on this
age-group was based on their greater likelihood of availability
for follow-up throughout the 5-year study period.
After considering 17 different types of morbidity-related
markers, the outcomes chosen for measurement in the plan-
ned 5-year longitudinal cohort studies were as follows:26
1. anthropometricmeasures: age-standardizedheight,weight,
body mass index, mid-upper arm circumference10,30,31;
2. blood hemoglobin3,9,32,33;
3. exercise tolerancemeasuredby the20-mshuttle run (beep)
test34–36;
4. health-related quality of life, measured by the standardized
Pediatric Quality of Life (PedsQL) survey instrument7,37; and
5. ultrasonography of the abdomen and liver (for S. mansoni)
or of the kidneys and bladder (for S. haematobium), using
standardized WHO protocols.38,39
At baseline, 62% of children in the selected S. mansoni
communities in Kenya and Tanzania had detectable eggs in
their stool and 10%had heavy infections (³ 400 eggs/g feces).
Heavy S. mansoni infections were associated with increased
baseline prevalence of anemia, although children with mod-
erate or heavy intensity infections had lower odds of having
physical wasting.
Prevalence of egg-positive infection in the combined
S. haematobium communities in Mozambique and Niger was
27%, with 5% of individuals having heavy infection (³ 50 eggs/
10mL urine). In contrast to the findings at the S. mansoni study
sites, at baseline, it was light intensity S. haematobium infec-
tions that were significantly associated with anemia. Theywere
also associated with lower scores in the social domain of the
standardizedPedsQL inventory survey. Individual country-level
baseline findings for Kenya and Tanzania have been published
elsewhere,8,40 and the baseline results from the four countries
that initiated subtle morbidity studies have been summarized
by country in tabular form by Shen and others.26
The Kenya and Tanzania gaining control studies were able
to successfully complete their Year 3 and Year 5 cohort
reexaminations.41–43 In a secondary analysis of their pooled
S. mansoni longitudinal data, overall infection intensity and
odds of infection were significantly reduced in both treatment
arms of the study.44 Furthermore, both annual CWT and
every-other-year SBT were associated with reduced odds of
undernutrition in Year 5 (at the time, the children were aged
12–13 years). They also had reduced odds of portal vein di-
lation on ultrasound, as compared with their baseline when
they were 7 or 8 years old. Although the prevalence of anemia
did not improve significantly, this may have been confounded
by increased malaria prevalence in the years following base-
line examination in Kenya; malaria was not assessed in Tan-
zania. For the combined Kenya and Tanzania cohorts, growth
stunting worsened in the areas receiving biennial SBT and
VO2max scores declined under both CWT and SBT regimens.
After adjusting for imbalance in startingprevalencebetween
the two study arms,44,45 children in communities receiving
annual CWT were found to have had significantly greater
reductions in infection prevalence and intensity than
those in communities receiving only biennial SBT. Although
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health-related quality-of-life scores improved in both study
arms, children in the CWT communities gained significantly
more. In aggregate, these SCORE findings suggested that
programs implementing annual CWT are likely to achieve
better overall S. mansoni morbidity control than those imple-
menting biennial SBT alone.44
SCHOOL BEHAVIORAL ASSESSMENT STUDY
There has been ongoing controversy about the public health
benefits of “deworming” via MDA and whether regular treat-
ments of school-aged children can improve their school per-
formance andcontribute to greater educational achievement.46
The SCORE investigators in Kenya attempted to rigorously in-
vestigate this issue by using a validated multidimensional
survey instrument, the Behavioral Assessment System for
Children (BASC-2), to assess emotional and behavioral prob-
lems among children in grades two through six.15 Thirty-six
children insix schoolswithinS.mansoni–endemiccommunities
near Lake Victoria were assessed both parasitologically and
with the BASC-2 Teacher Rating Scale, both before and
3 weeks after MDA delivery. Teachers were blinded to the in-
fection status of these participating children. Following this
initial assessment of behavior using theBASC-2, studychildren
were given praziquantel by MDA using a standard SBT ap-
proach, along with all other children in their schools. Then, the
BASC-2 was repeated for the same children who had com-
pleted the pre-MDA BASC-2 assessment.
Participating children’s BASC-2 scores improved significantly
after treatment in each of the “problem” behavioral categories,
with fewer externalizing problems (hyperactivity, aggression, and
conduct problems that are disruptive in nature), internalizing
problems (anxiety, depression, somatization, atypicality, and
withdrawal), andschool problems (academicdifficulties, attention
problems, and learning problems).15 Changes in BASC scores
were seen in both egg-positive and egg-negative children.
A high level of heterogeneity in behavior score changeswas
observed among childrenwhowere initially egg negative, with
posttreatment scores not changing much for some egg-
negative children but changing dramatically for others. This
could reflect the fact that because of its limited diagnostic
sensitivity, a negative Kato–Katz stool examination in an
S. mansoni–endemic zone does not exclude the presence of
symptomatic low-level chronic infection.47–50 Because such
low intensity infections often go undetected by stool testing,
our posttreatment behavioral findings among egg-negative
children suggests that their praziquantel MDA likely had a
treatment-specific impact on their performance. It supports
the concept that MDA can improve school performance and
have a greater effect in endemic areas than that measured by
only focusing on treatment impacts for S. mansoni egg-
positive children.
META-ANALYSIS OF COGNITION AND SCHOOL
PERFORMANCE OUTCOMES
The SCORE’s Rapid Answers Project initiative51 used sys-
tematic reviews andmeta-analysis of available data to answer
other policy-relevant questions about schistosomiasis mor-
bidity control. Two of these projects involved assessment of
the impact of active infection and its drug therapy on risk of
morbidity due to Schistosoma infections.14,38 Brief graphical
summaries of their findings are provided in Supplemental
information File S1 and File S2.
First, in developing a meta-analysis of the effects of in-
fection and treatment on children’s cognition and school
performance, we performed a systematic review of the avail-
able published data before 2016.14 Although there was a rel-
atively large body of published reports and studies on
childhood cognitive development and school performance,
the variability in study quality necessitated a critical synthesis
of their aggregate findings. A SCORE-affiliated team headed
by Dr. Amara E. Ezeamama performed a systematic review of
more than 2,900 articles and produced a meta-analysis of 30
relevant studies.14
Our findings from themeta-analysis indicated that compared
with uninfected children or with children who received prazi-
quantel treatment, children who had active Schistosoma in-
fection or who had not been treated had significant deficits in
school attendance and scholastic achievement and deficits in
formal tests of learning and memory.14 By contrast, there were
no significant differences between the two groups in tests of
reaction time or of innate intelligence. Schistosoma infection–
related deficits in learning andmemory tests, but not scholastic
achievement,were invariant to studydesignacross the rangeof
observational and interventional studies included in the meta-
analysis.
META-ANALYSIS OF DRUG-MEDIATED REDUCTION IN
SCHISTOSOMA INFECTION INTENSITY AND ITS EFFECTS
ON INFECTION-ASSOCIATED MORBIDITY
Praziquantel treatment is not completely curative for Schis-
tosoma infections, particularlywhenheavy infection ispresent.52
Furthermore, praziquantel does not protect against rapid re-
infection of those who live in high-risk environments.53,54 How-
ever, most individuals do experience a considerable reduction in
the intensity of their Schistosoma infections after treatment,
which has often been assumed to be a proxy for decreased
overall morbidity.
Our second morbidity-related meta-analysis evaluated the
actual scale of morbidity reduction when treatment reduces in-
tensity of infection, even in the absence of cure.38 The SCORE
also wished to determine whether there is a way to translate
commonly reported “egg reduction ratios” into a quantifiable
morbidity reduction benefit. The aim was to provide a conver-
sion factor tocapture “morbiditycontrol” for latercost-effectiveness
studies that would compare different schistosomiasis control
strategies.55
The SCORE partners, led by Dr. Gisele N. Andrade, con-
ducted a systematic review of 309 studies that recorded
morbidity levels in affected individuals or populations before
and after drug treatment interventions.38 A technique called
meta-regression was performed to correlate the observed
reductions in parasite egg outputs with the posttreatment
reductions in measured morbidity prevalence.
The study found that larger reductions in measured egg
output following treatment were indeed correlated with lower
odds of continuing to havemost kinds of infection-associated
morbidity. Specifically, forS.mansoni andS. japonicum, more
profound reductions in egg output were linked with less liver
morbidity, and forS. haematobium, better treatment response
in terms of egg output was linked to reduced odds of urinary
tract bleeding and deformity.38 Thus, despite posttreatment
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persistence of active infections, the meta-analysis results
suggested that even if total elimination of egg output is not
achievable in all patients within endemic areas, MDA can still
result in significant reductions in Schistosoma-associated
morbidity prevalence if average reductions of egg output
of ³ 90% are achieved.
SUMMARY AND NEXT STEPS
There is a need to better define the impact of Schistosoma
infection in early childhood and its effects on concurrent and
cumulative scholastic achievement.56 Such loss of human
capital may actually represent the bulk of schistosomiasis-
related disability within endemic areas.57
The SCORE morbidity studies, by adding new markers for
physical and psychological functioning, provided better focus on
the impact of Schistosoma infection on human performance.
However, thestudies’scopewasstill limitedbyavailable resources,
and in some cases, the effects of treatment in reducing morbidity
were smaller thanexpected.Now, in follow-up to our assessments
of functional morbidities, we think that larger cohort studies, in-
volving different age-groups, additional testing, and tracking of
coinfections,diet,andothereffectmodifiersareclearlyneeded.58 In
follow-up to theSCOREBASC-2behavior study,15moreextensive
and more detailed psychological and behavioral studies will help
triangulate and refine estimates of the overall impact of Schisto-
soma infection on childhood scholastic performance.
The analyses presented here reinforce the need for a
complete reassessment of DALYs related to schistosomiasis.
The number of morbidities included in DALY disability
weighting needs to be expanded, and the often subcurative
effect of praziquantel needs to be considered in case count
estimation. One of the approaches buttressing the calculation
of DALYs in the Global Burden of Disease program is the
“counterfactual,” that is, what global burden would be like if
the disease came under control or were eliminated?59 Current
DALY estimates based on Schistosoma infection intensity
assume that the prevalence of high-intensity infections is
declining in the face of MDA implementation. This is not al-
ways true,60 and we suggest that newer estimates of persis-
tent posttreatment infection be included in DALY calculations
for schistosomiasis. These changes would provide a more
realistic valuation of the schistosomiasis-associated DALYs
that can be averted through MDA intervention.
Current WHO targets for control are primarily focused on re-
ducing infection intensity.21 There is a clear need to redefine the
required community-level prevalence targets for effective “mor-
bidity control.” Large-scale initiatives such as the Morbidity Op-
erational Research for Bilharziasis Implementation Decisions
(MORBID) study61 arebeingplanned tomoreclearly demonstrate
the level of post-MDA community infection prevalence and in-
tensity that are associated with persistent disease, in terms of
bothanatomical and functionalpathology.Theuseofnewermore
sensitive point-of-care rapid diagnostics62 for both infection and
morbiditywill facilitate thisassessment.Movingbeyondtheuseof
egg-countingdiagnostics,whichunderestimate theprevalenceof
low-intensity infections,50,63–66 should enhance our ability to de-
termine the attributable role of Schistosoma infections in widely
prevalent multicausal pathologies such as anemia, growth
stunting, cognitive dysfunction, depression, and infertility. This
expanded knowledgewill be critical for accurate estimation of the
actual worldwide disease burden of Schistosoma infections and
for optimal decision-making regarding health policy investment
and development.58
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